Drug Trial Radar · NCT00077493
BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
Last checked: Nov 20, 2026Latest source record: Dec 28, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
95
Planned (sponsor's estimate)
Start
Jan 2004
Primary completion
Oct 2008
Study completion Oct 2008
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Cambridge Antibody Technology
- First posted
- Feb 12, 2004
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 months, up to 24 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: BL22 immunotoxin can locate tumor cells and kill them without harming normal cells. BL22 immunotoxin may be effective in treating relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma. PURPOSE: This phase I trial is studying the side effects and best dose of BL22 immunotoxin in treating young patients with relapsed or refractory acute lymphoblastic leukemia or non-Hodgkin's lymphoma.
Conditions
- Leukemia
- Lymphoma
Interventions
BL22 immunotoxinDrug
BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 OR on days 1, 3, 5, 7, 9, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) or unconfirmed CR (CRu) receive 2 additional courses beyond CR or CRu for a maximum of 6 courses.
antibody-drug conjugate therapyProcedure
CD22 antibody, RFB4 on day 7
immunotoxin therapyProcedure
tested for immunogenicity to CAT-8015 before each cycle and at end of study.
monoclonal antibody therapyProcedure
administered intravenously over 30 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- assessment of efficacy, safety, pharmacokinetics, immunogenicity.Time frame: end of study
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
Bethesda, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.